Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Top Three among Disruptive Dozen Technologies: The Future of Cancer Therapies @2016 World Medical Innovation Forum

Reporter: Aviva Lev-Ari, PhD, RN

3. Liquid Biopsy for Oncology – Shyamala Maheswaran, PhD

• circulating tumor cells – RNA with fragments DNA and protein expresssion – heterogeneity between cells
• target drugs to mutations
• blood based derived tests
• interogate cells
• Exosomes
• circulating DNA
• drug sensitivity tests – evolution of the cells under terapy

2. Immune Modulators (Checkpoint Inhibitors) and Vaccines – Antonio Chicca, MD, PhD

• CAR -T
• cancer cells are immune invading

1. Cellular Immunotherapy – Chimeric Antigen Receptor – T – Marcela Maus, MD, PhD, Director Cellular Immunotherapy, MGH

• Blood cancers
• New targets for Solid tumors
• use other disruptor technologies CRISPR, Epigenetics
• Global Reach

SOURCE

Disruptive Dozen Technologies: The Future of Cancer Therapies @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston

LIVE 11:25 am – 12:25 pm 4/27/2016 Disruptive Dozen Technologies: The Future of Cancer Therapies @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston